Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited held its Annual General Meeting on May 27, 2025, where all resolutions on the agenda were successfully carried. Key resolutions included the re-election of directors Dianne Angus and Jenny Harry, approval of auditor fees, and an increase to the non-executive director fee pool. The outcomes reflect strong shareholder support and are likely to ensure continued stability and strategic direction for the company.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company primarily targets conditions such as Rett syndrome and Fragile X syndrome, aiming to address significant unmet medical needs in these areas.
Average Trading Volume: 781,892
Technical Sentiment Signal: Hold
Current Market Cap: A$1.64B
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.